CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 50 enrolled
Drug / intervention
Azacitidine (AZC) +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01812252
NCT01812252Phase 2Completed
CompareCT.gov

Initial Cytoreductive Therapy for Myelodysplastic Syndrome Prior to Allogeneic Hematopoietic Cell Transplantation (the ICT-HCT Study)

Fred Hutchinson Cancer Center·interventional·Posted Mar 18, 2013·Updated Feb 15, 2024

In Brief

A Phase 2 clinical trial evaluating Azacitidine (AZC), Decitabine, and 1 other intervention for Chronic Myelomonocytic Leukemia and 3 related conditions. Completed, enrolled 50 participants across 4 sites.

Detailed Summary

This randomized clinical trial studies different chemotherapies in treating patients with myelodysplastic syndrome before donor stem cell transplant. Giving chemotherapy before a donor stem cell transplant helps stop the growth of cancer cells in the bone marrow, including normal blood-forming cells (stem cells) and cancer cells, and may prevent the myelodysplastic syndrome from coming back after the transplant. When the healthy stem cells from a donor are infused into the patient they may help the patient's bone marrow make stem cells, red blood cells, white blood cells, and platelets.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsChronic Myelomonocytic Leukemia, de Novo Myelodysplastic Syndrome, Myelodysplastic Syndrome, Secondary Myelodysplastic Syndrome
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedMar 18, 2013
Enrollment StartAug 19, 2013
Primary CompletionOct 26, 2022
TodayJul 2, 2026
Enrollment to primary: 9.2 yearsPosted 13.3 years ago

Interventions

Azacitidine (AZC)drug

Given IV or SC

Decitabinedrug

Given IV or SC

Quality-of-Life Assessmentother

Ancillary studies